No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability
Cantor Fitzgerald Initiates Travere Therapeutic(TVTX.US) With Buy Rating
Cantor Fitzgerald Initiates Travere Therapeutics at Overweight
BofA Securities Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Announces Target Price $24
Travere Therapeutics Insider Sold Shares Worth $258,278, According to a Recent SEC Filing
J.P. Morgan's Top Healthcare Stocks for 2025